Provided by Tiger Trade Technology Pte. Ltd.

EyePoint

16.24
+0.25001.56%
Volume:258.39K
Turnover:4.18M
Market Cap:1.34B
PE:-5.42
High:16.41
Open:16.03
Low:15.81
Close:15.99
52wk High:19.11
52wk Low:3.91
Shares:82.79M
Float Shares:59.91M
Volume Ratio:0.36
T/O Rate:0.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.9984
EPS(LYR):-2.3246
ROE:-98.23%
ROA:-49.39%
PB:6.72
PE(LYR):-6.99

Loading ...

EyePoint Pharmaceuticals Inc - Prices Public Offering of 11 Mln Shares at $12.00 per Share

THOMSON REUTERS
·
Oct 15

EyePoint $150M Spot Secondary; price range $12.00-$12.50

TIPRANKS
·
Oct 15

BRIEF-Eyepoint Pharmaceuticals Inc Files For Mixed Shelf Size Not Disclosed - SEC Filing

Reuters
·
Oct 15

EyePoint Pharmaceuticals Inc - Proceeds to Advance Duravyu™ Development for Wet Amd and Dme

THOMSON REUTERS
·
Oct 15

EyePoint Announces Proposed Public Offering of Common Stock

GlobeNewswire
·
Oct 15

EyePoint Pharmaceuticals Launches Phase 3 DURAVYU Program

TIPRANKS
·
Oct 15

EyePoint Pharmaceuticals Inc Files for Mixed Shelf; Size Not Disclosed - SEC Filing

THOMSON REUTERS
·
Oct 15

EyePoint Pharmaceuticals Inc - Announces Phase 3 Program Initiation for Duravy in Diabetic Macular Edema

THOMSON REUTERS
·
Oct 15

EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema

GlobeNewswire
·
Oct 15

EyePoint reports inducement grants under NASDAQ listing rule

TIPRANKS
·
Sep 16

EyePoint Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Sep 16

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Sep 16

EyePoint Announces Participation at Upcoming Investor Conferences

GlobeNewswire
·
Aug 26

BRIEF-EyePoint Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Aug 19

EyePoint Pharmaceuticals Inc : Mizuho Raises Target Price to $28 From $26

THOMSON REUTERS
·
Aug 15

Mizuho Adjusts Price Target on EyePoint Pharmaceuticals to $28 From $26, Maintains Outperform Rating

MT Newswires Live
·
Aug 15

EyePoint Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Aug 07

Stock Track | EyePoint Pharmaceuticals Plunges 5.88% Pre-Market on Disappointing Q2 Results and Increased Losses

Stock Track
·
Aug 06

Stock Track | EyePoint Pharmaceuticals Plunges 5.88% Pre-Market on Q2 Revenue Miss and Widening Losses

Stock Track
·
Aug 06

EyePoint Q2 revenue falls 44%, net loss widens

Reuters
·
Aug 06